In a rodent model, a novel GLP-1R/GIPR/GCGR triple agonist, SAR441255, has been shown to promote weight loss and the maintenance of healthy blood glucose levels and is superior to the GLP-1R/GCGR dual agonist (Saxena et al., 2023)
Indeed, reports that sAC / mice display impairments in both pancreatic insulin secretion and intraperitoneal glucose tolerance (40, 43) support our findings implicating sAC in GLP-1(2836) and/or overall GLP-1 biology
This is a great question that comes up a lot
Salem U, Kumar VA, Madewell JE, Schomer DF, de Almeida Bastos DC, Zinn PO, Weinberg JS, Rao G, Prabhu SS, Colen RR
But its effectiveness can sometimes come at too steep a price if you dont do your homework correctly
The converse is also true